oculocerebral hypopigmentation syndrome, Cross type

disease
On this page

Also known as Cross syndromehypopigmentation oculocerebral syndrome Cross typeKramer syndromeoculocerebral hypopigmentation syndromeOculocerebral Syndrome with Hypopigmentation

Summary

oculocerebral hypopigmentation syndrome, Cross type (MONDO:0009767) is a disease and 3 clinical trials. A subtype of syndromic oculocutaneous albinism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 45
  • Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families14WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

45 HPO clinical features (Orphanet curated; top 45 by frequency):

HPO IDTermFrequency
HP:0000174Abnormal palate morphologyVery frequent (80-99%)
HP:0000963Thin skinVery frequent (80-99%)
HP:0001249Intellectual disabilityVery frequent (80-99%)
HP:0004322Short statureVery frequent (80-99%)
HP:0000028CryptorchidismFrequent (30-79%)
HP:0000160Narrow mouthFrequent (30-79%)
HP:0000268DolichocephalyFrequent (30-79%)
HP:0000463Anteverted naresFrequent (30-79%)
HP:0000478Abnormality of the eyeFrequent (30-79%)
HP:0000504Abnormality of visionFrequent (30-79%)
HP:0000518CataractFrequent (30-79%)
HP:0000639NystagmusFrequent (30-79%)
HP:0000656EctropionFrequent (30-79%)
HP:0000691MicrodontiaFrequent (30-79%)
HP:0001107Ocular albinismFrequent (30-79%)
HP:0001166ArachnodactylyFrequent (30-79%)
HP:0001251AtaxiaFrequent (30-79%)
HP:0001257SpasticityFrequent (30-79%)
HP:0001347HyperreflexiaFrequent (30-79%)
HP:0001376Limitation of joint mobilityFrequent (30-79%)
HP:0001510Growth delayFrequent (30-79%)
HP:0001903AnemiaFrequent (30-79%)
HP:0002071Abnormality of extrapyramidal motor functionFrequent (30-79%)
HP:0002353EEG abnormalityFrequent (30-79%)
HP:0002510Spastic tetraplegiaFrequent (30-79%)
HP:0003196Short noseFrequent (30-79%)
HP:0005280Depressed nasal bridgeFrequent (30-79%)
HP:0007256Abnormal pyramidal signFrequent (30-79%)
HP:0007957Corneal opacityFrequent (30-79%)
HP:0008056Aplasia/Hypoplasia affecting the eyeFrequent (30-79%)
HP:0100022Abnormality of movementFrequent (30-79%)
HP:0000023Inguinal herniaOccasional (5-29%)
HP:0000071Ureteral stenosisOccasional (5-29%)
HP:0000079Abnormality of the urinary systemOccasional (5-29%)
HP:0000252MicrocephalyOccasional (5-29%)
HP:0000407Sensorineural hearing impairmentOccasional (5-29%)
HP:0000545MyopiaOccasional (5-29%)
HP:0001139ChoroideremiaOccasional (5-29%)
HP:0001172Abnormal thumb morphologyOccasional (5-29%)
HP:0001305Dandy-Walker malformationOccasional (5-29%)
HP:0001608Abnormality of the voiceOccasional (5-29%)
HP:0002305AthetosisOccasional (5-29%)
HP:0005561Abnormality of bone marrow cell morphologyOccasional (5-29%)
HP:0005599Hypopigmentation of hairOccasional (5-29%)
HP:0007730Iris hypopigmentationOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical nameoculocerebral hypopigmentation syndrome, Cross type
Mondo IDMONDO:0009767
OMIM257800
Orphanet2719
SNOMED CT17827007
UMLSC2936910
MedGen423639
GARD0000105
NORD1520
Is cancer (heuristic)no

Also known as: Cross syndrome · hypopigmentation oculocerebral syndrome Cross type · Kramer syndrome · oculocerebral hypopigmentation syndrome · Oculocerebral Syndrome with Hypopigmentation

Disease family

This is a subtype of syndromic oculocutaneous albinism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic diseasesyndromic oculocutaneous albinismoculocerebral hypopigmentation syndrome, Cross type

Related subtypes (3): Chediak-Higashi syndrome, Griscelli syndrome, Hermansky-Pudlak syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified3

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06739889Not specifiedACTIVE_NOT_RECRUITINGEffects of ELAVl and CDOA vs Upper Thoracic Mobilization on Forward Head Posture in Upper Cross Syndrome
NCT06766955Not specifiedNOT_YET_RECRUITINGPrevalence of Lower Cross Syndrome Among Female College Students and Its Relation With Dysmenorrhea
NCT04668040Not specifiedCOMPLETEDComparison of Stretching and MET in Lower Cross Syndrome

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.